Evidence map›Paper›PMID 38042969›Full record

ArticleThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease2023

Standards for clinical trials for treating TB.

P du Cros, J Greig, J-W C Alffenaar, G B Cross, C Cousins, C Berry, U Khan, P P J Phillips, G E Velásquez, J Furin and 30 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

40 authors.

P du CrosBurnet Institute, Melbourne, VIC, Monash Infectious Diseases, Monash Health, Melbourne, VIC, Australia.
J GreigBurnet Institute, Melbourne, VIC, Médecins Sans Frontières (MSF), Manson Unit, London, UK.
J-W C AlffenaarSydney Infectious Diseases Institute (Sydney ID), and, School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Westmead Hospital, Sydney, NSW.
G B CrossBurnet Institute, Melbourne, VIC, Kirby Institute, University of New South Wales, Sydney, NSW, Australia.
C CousinsDepartment of Pharmacology and Therapeutics, University of Liverpool, Liverpool, Institute of Clinical Trials and Methodology, University College London, London, UK.
C BerryMédecins Sans Frontières (MSF), Manson Unit, London, UK.
U KhanInteractive Research and Development Global, Singapore City, Singapore.
P P J PhillipsUCSF Center for Tuberculosis, Division of Pulmonary and Critical Care Medicine, and.
G E VelásquezUCSF Center for Tuberculosis, Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA.
J FurinHarvard Medical School, Department of Global Health and Social Medicine, Boston, MA.
M SpigelmanGlobal Alliance for TB Drug Development, New York, NY, USA.
J T DenholmVictorian Tuberculosis Program, Melbourne Health, Melbourne, VIC, Department of Infectious Diseases, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.
S S ThiEswatini National TB Control Program, Mbabane, Kingdom of Eswatini.
S TiberiBlizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, GlaxoSmithKline, London, UK.
G K L HuangBurnet Institute, Melbourne, VIC, Northern Health Infectious Diseases, Northern Health, Melbourne, VIC.
G B MarksSchool of Clinical Medicine, University of New South Wales, Sydney, NSW, Australia.
A TurkovaMedical Research Council Clinical Trials Unit at University College London, London, UK.
L GuglielmettiMédecins Sans Frontières (MSF), Paris, Sorbonne Université, Institut national de la santé et de la recherche médicale, Unité 1135, Centre d'Immunologie et des Maladies Infectieuses, Paris, Assistance Publique Hôpitaux de Paris (APHP), Groupe Hospitalier Universitaire Sorbonne Université, Hôpital Pitié-Salpêtrière, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries, Paris, France.
K L ChewDepartment of Laboratory Medicine, National University Hospital, Singapore City, Singapore.
H T NguyenResearch Department, Friends for International TB Relief, Ha Noi, Vietnam.
C W M OngInfectious Diseases Translational Research Programme, Department of Medicine, National University of Singapore, Singapore City, Division of Infectious Diseases, Department of Medicine, National University Hospital, Singapore City, Institute of Healthcare Innovation & Technology, National University of Singapore, Singapore City, Singapore.
G BrigdenThe Global Fund, Geneva, Switzerland.
K P SinghDepartment of Infectious Diseases, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia, Victorian Infectious Disease Unit, Royal Melbourne Hospital, Melbourne, VIC, Australia.
I MottaMSF, Geneva, Switzerland.
C LangeDivision of Clinical Infectious Diseases, Research Center Borstel, Borstel, German Center for Infection Research (DZIF), TTU-TB, Borstel, Respiratory Medicine & International Health, University of Lübeck, Lübeck, Germany, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, USA.
J A SeddonDepartment of Infectious Disease, Imperial College London, London, UK, Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg, South Africa.
B-T Nyang'waPublic Health Department, Operational Center Amsterdam (OCA), MSF, Amsterdam, The Netherlands.
A K J MaugDamien Foundation Bangladesh, Dhaka, Bangladesh.
M T GlerDe La Salle Medical and Health Sciences Institute, Dasmariñas, the Philippines.
K E DooleyDivision of Infectious Diseases, Vanderbilt University Medical Center, Nashville, TN, USA.
M QuelapioTropical Disease Foundation, Makati City, Manila, the Philippines, KNCV Tuberculosis Foundation, The Hague, The Netherlands.
B TsogtMongolian Anti-TB Coalition, Ulaanbaatar, Mongolia.
D MenziesRespiratory Epidemiology and Clinical Research Unit, Montreal Chest Institute & McGill International TB Centre, Montreal, QC, Canada.
V CoxCentre for Infectious Disease Epidemiology and Research, School of Public Health and Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town.
C M UptonTASK Applied Science, Cape Town, South Africa.
A SkrahinaThe Republican Scientific and Practical Center for Pulmonology and TB, Minsk, Belarus.
L McKennaTreatment Action Group, New York, NY.
C R HorsburghDepartments of Global Health, Epidemiology, Biostatistics and Medicine, Schools of Public Health and Medicine, Boston University, Boston MA, USA.
K DhedaCentre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine and UCT Lung Institute & South African MRC/UCT Centre for the Study of Antimicrobial Resistance, University of Cape Town, Cape Town, South Africa, Faculty of Infectious and Tropical Diseases, Department of Immunology and Infection, London School of Hygiene & Tropical Medicine, London, UK.
B J MaraisSydney Infectious Diseases Institute (Sydney ID), and, The Children's Hospital at Westmead, Sydney, NSW, WHO Collaborating Centre in Tuberculosis, The University of Sydney, Sydney, NSW, Australia.

Funding

DRAMATIC Phase 2 Duration Randomized MDR-TB Treatment TrialU01AI152980 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Charles Robert Horsburgh, PAYAM NAHID · 2020 to 2026
$7.5M
Predictors of Resistance Emergence Evaluation in MDR-TB Patients on Treatment (PREEMPT)R01AI134430 · NIAID · BOSTON UNIVERSITY MEDICAL CAMPUS · PI HORSBURGH, CHARLES ROBERT, STERLING, TIMOTHY R · 2017 to 2021
$4.6M
Transmission Of Tuberculosis Among illicit drug use Linkages (TOTAL)R01AI147316 · NIAID · BOSTON MEDICAL CENTER · PI JACOBSON, KAREN R · 2019 to 2023
$3.5M
Optimal targeting for individual and population-level TB preventionR01AI146555 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI MENZIES, NICOLAS A · 2020 to 2024
$2.5M
Safety and tolerability of new and repurposed drugs for MDR-TB treatmentK08AI141740 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI VELASQUEZ, GUSTAVO EDUARDO · 2019 to 2023
$985k
Mentoring Investigators in HIV and Tuberculosis Therapeutics ResearchK24AI150349 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DOOLEY, KELLY E. · 2020 to 2025
$789k
NIAID NIH HHS K08 AI141740NIAID NIH HHS K24 AI150349NIAID NIH HHS R01 AI134430NIAID NIH HHS R01 AI146555NIAID NIH HHS R01 AI147316NIAID NIH HHS U01 AI152980
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

TuberculosisBiological Specimen BanksClinical Trials as TopicHumans

Identifiers

PMID38042969
PMCPMC10719894

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.